| Updates AUROPHARMA : Aurobindo Pharma Limited has informed the Exchange regarding We refer to our earlier letter dated November 28, 2019 informing about entering into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., USA., a clinical-stage vaccine development company by Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of the Company. | 13/Feb/2020 |
